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In this issue, Williams et al. describe the palliative effect of
intraarticular injections of hyaluronic acid in a fibronectin
(FN)-fragment-induced model of osteoarthritis (OA)1. The
general concept of FN fragments as harbingers of biologic
activity stems from early experiments in which proteolytic
treatment of plasma-derived FN was observed to yield
globular domains that retained capacities to engage other
extracellular matrix (ECM) ligands or cells. This premise
eventually led to the characterization of FN as a multivalent
adhesive glycoprotein possessing binding domains for sev-
eral other ECM molecules, as well as an ‘active’ cell-
binding arginine-glycine-aspartic acid (RGD) motif located
within the tenth type III structural repeat (counting from N-
to C-terminus) (reviewed in references 2–4).
Subsequently, there has been an ‘explosion’ in FN
research, with a particularly important breakthrough com-
ing from the work of Damsky and colleagues, who dis-
sected the mechanism by which a fragment of FN can
trigger an altered profile of cellular responses compared to
that promoted by intact FN5,6. Specifically, they showed
that the capacity of a FN fragment to induce matrix metal-
loproteinase (MMP) expression in synoviocytes was due to
absence of an additional integrin recognition site that
was retained in intact FN6. This work ushered in the
concept that different molecular forms of FN can extract
variable responses from cells according to their respective
complements of integrin recognition sites.
As recently as ten years ago, it was believed that the
capacity of FN subunits to interact with cells was largely
attributable to two major recognition regions, respectively
centered in the tenth type III repeat (see above) and in
the vicinity of the alternatively spliced V segment (V for831‘variable’, as it does not conform with any of the three
repeating structural motifs of FN)2–4,7. The situation has
subsequently become much more complicated, with
the realization that FN is comprised of a multitude of
potential cell recognition sites. For example, it is now
apparent that virtually all of the type III structural repeats
within the FN subunit, which number between 15 and 17
depending upon inclusion of two alternatively spliced ‘extra’
type III repeats (EIIIA and EIIIB), constitute potential 1
integrin-binding domains8. Even the N-terminal heparin
binding domain, composed of five type I structural repeats,
has been observed to bind 51 integrin on fibroblasts,
triggering adhesion, signal transduction, and cytoskeletal
reorganization9.
Therefore, FN appears to be a virtual ‘keyboard’ of
binding sites, upon which various ‘chords’ of integrins can
be ‘played’ by cells. Based on the model set forth by
Damsky et al.5,6, a reasonable working hypothesis is that
FN fragments are preferentially active toward chondrocytes
because they contain reduced numbers of such recognition
sites in comparison to intact FN. Consequently, fragments
engage reduced clusters of integrins at the chondrocyte
surface, thereby promoting signal transduction that is per-
ceived as ‘disharmonious’. Potentially, such reduced
integrin engagement triggers a shift away from
chondrocyte-specific gene expression (‘GOOD’) toward a
catabolic response (‘BAD’) (Fig. 1). This would appear to
be a useful model to explain why FN fragments trigger
chondrolysis, whereas intact FN does not. However, it does
not exclude the possibility that FN could also contain cryptic
sites that become recognizable at the chondrocyte surface
following release of conformational restraints through pro-
teolysis10,11. Nor does the scenario described above pre-
dict a ‘one integrin per FN structural repeat’ relationship. In
any given instance, it is likely that specific sites of engage-
ment would comprise more than one structural repeat,
considering the relatively large size of integrins in compari-
son to such repeats12. Of additional note, FN fragments are
likely to possess altered affinity for other ECM molecules,
potentially affecting their capacity for diffusion and
deposition in the cartilage matrix13,14.
If this were not complicated enough, the FN ‘keyboard’
is changeable. In addition to a variety of potential
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cartilage (LEFT), intact FN possesses multiple domains (in this
schematic, four) available for binding to integrins situated at the
chondrocyte surface. Outside-in signaling occurs, triggering signal
transduction for chondrocyte-specific gene expression in the
nucleus (‘GOOD’). In the OA joint (RIGHT), FN fragments are
abundant, leading to prevalence of smaller clusters of FN-engaged
integrins on the surfaces of chondrocytes. This in turn leads to an
alteration in signal transduction with promotion of catabolic gene
expression in the nucleus (‘BAD’).Is FN-fragment-induced arthritis a model of OA
or actual OA?
FN fragments are abundant in synovial fluid and carti-
lage of OA joints14,30,31,38, and therefore are situated at the
right place and the right time to be involved in the ongoing
process of OA. Homandberg and colleagues are to be
applauded for originating the concept of FN fragment-
mediated chondrolysis in vitro and for developing an animal
model of this process13,16–18,20–22,25,38–40. Although it
would probably be overly zealous to assume that
FN-fragment induced arthritis is OA, this experimental
model seems to be very close to the real thing. As
described in the study in this issue, FN fragments induce a
joint malady with striking resemblances to OA, including
depletion of surface cartilaginous proteoglycans, joint
swelling, and bone spurring1. There are now a number of
animal models used to study OA and their relative merits
continue to be much debated41,42. The model used bypost-translational modifications, FN subunits are also sub-
ject to alterations in primary structure on the basis of
alternative splicing of a primary mRNA transcript2–4,15.
Thus, in addition to 20 human FN subunits that are possible
through inclusion or exclusion of sequences within the
alternatively spliced EIIIA, EIIIB, and V segments, several
additional cartilage-specific forms are possible. The func-
tion of such isoforms, in which the V segment plus the 15th
type III and the tenth type I repeat are excluded [designated
(V+C)-forms], and which account for up to ∼80% of carti-
lage FN4,15, is currently unknown.
A growing body of data indicates that fragment species
derived from almost any part of FN possess the capacity to
trigger catabolic gene expression in chondrocytes16–26
(Fig. 2). With the exceptions of the alternatively spliced
EIIIB segment and extreme C-terminal sequences, neither
of which have yet been tested, ‘chondrocyte active’ frag-
ments span virtually the entire FN subunit. The seeming
randomness of this distribution might appear to be unten-
able until one considers that the distribution of potential
binding sites for cell surface receptors may be equally as
widespread. For example, five of the active fragments
depicted in Fig. 2 contain at least one integrin recognition
site (fragments A and C-F)2–4,7,9,27, and three of these are
known to contain more than one site (fragments C, D and
F)7,8,28. Furthermore, the 50 kDa gelatin-binding domain
(fragment B, Fig. 2), while apparently unable to directly
engage integrins, has the capacity to bind to integrin-
associated tissue transglutaminase, thereby promoting
cellular recognition29. Additional potential cell surface
receptors for FN include heparin sulfate and chondroitin
sulfate proteoglycans, which interact with sites in the 12th
through 14th type III repeats2–4.
In addition to serving as the substrate for generation of
‘chondrocyte active’ fragments in OA, FN could also exert
catabolic effects through alternative splicing. Of particular
interest in this regard is the alternatively spliced EIIIAsegment (fragment E, Fig. 2), which is expressed in carti-
lage and synovial fluid in OA but not in healthy carti-
lage30,31, and which in recombinant form has been
observed to trigger MMP expression by cultured chondro-
cytes23. Although the mechanism by which chondrocytes
engage this segment is not yet known, both the EIIIA and V
segments are recognized by 41 integrins on other cell-
types4,7,27. Furthermore, the 4 integrin subunit, which is
not normally expressed in cartilage, is found on chondro-
cytes in OA, where it is available for dimerization with 1
subunits32–34. These observations raise the intriguing
possibility that the alternatively spliced EIIIA and V seg-
ments, and possibly additional constantly-expressed type
III repeats, could engage chondrocyte 41 integrins within
the ECM of OA cartilage4,7,8,27,28. Such interactions, which
would not be possible in healthy cartilage, could potentially
trigger catabolic gene expression by OA chondrocytes23,24.
Although integrin recognition seems very likely to play a
role in the stimulation of chondrocytes by FN fragments,
additional mechanisms for cellular activation by partial FNs
have been proposed, and these could have significance
with respect to the catabolic actions of such fragments on
cartilage matrix. For example, in addition to its capacity to
stimulate MMP expression in chondrocytes and synovial
cells23, the EIIIA segment has been observed to activate
the Toll-like receptor 4 in non-chondrocytic human cells35.
This is one of a class of molecules that triggers a signaling
cascade in response to bacterial lipopolysaccharide
(LPS)36. In cartilage, LPS has long been known to trigger
catabolic activity comparable to that of inflammatory
cytokines such as interleukin-1 and tumor necrosis factor
37. Of note, in the study by Okamura et al.35, controls were
performed to show that the EIIIA activity was heat-
sensitive, yet unaffected by polymyxin B or an LPS antag-
onist, thereby ruling out the possibility that the observed
effects could be due to LPS contamination of the recom-
binant protein preparation. A second recent study indicates
a potential role of the IL-1 receptor in cartilage-specific
collagen degradation induced by a FN fragment comprised
of the C-terminal heparin binding domain and the alterna-
tively spliced V segment (fragment F, Fig. 2)24. It is clear
that much work still needs to be done to establish the
relative roles of these mechanisms compared to integrin
receptor activation in mediating the catabolic effects of FN
fragments on cartilage.
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consideration as a useful experimental system.Fig. 2. ‘Any way you cut it . . .’ A diverse set of FN fragments have been observed to trigger catabolic responses in chondrocytes. Shown at
the top is a schematic diagram of the FN subunit with N-terminus at the left and C-terminus at the right. This is composed of repeating
structural motifs designated as type I, type II, and type III repeats. Globular domains with capacities to bind to other ECM ligands or cells are
denoted by brackets, as are known sites of recognition of FN by cell-surface integrins (‘cell’). The three major sites of alternative splicing are
denoted by the letters B and A, for ‘extra type III repeats B and A’, and V, for ‘variable region’. Below the diagram of the intact subunit
are six partial FNs (FN fragments) (lettered A through F) that have been observed to trigger catabolic responses in cultured chondrocytes
or cartilage explants. These responses, in addition to potentially catabolic responses, are listed below in the key. With the exception of the
EIIIA segment (E), which was recombinant, all of the fragments tested were purified from proteolytic digests of plasma-derived FN. The
extended line connecting type III repeats in partial FNs C and D reflect the absence of the alternatively spliced EIIIB and EIIIA segments at
these sites in plasma-derived FN, the source of these fragments.
Partial fibronectins Demonstrated effects
A. 29 kDa N-terminal heparin-binding domain 116,216,19,3,417,520,11–1726,1825
B. 50 kDa gelatin binding domain 1,216,3,417
C. 120 kDa central cell-binding fragment 219
D. 140 kDa central cell-binding fragment 1,216,3,417,520
E. Alternatively spliced EIIIA segment 1,623
F. 40 kDa C-terminal heparin-binding domain 1,7,8,9,1024
Key
1. Proteoglycan release from cartilage explant
2. Protease release from cartilage explant
3. Decreased protein synthesis by cartilage explant
4. Decreased proteoglycan synthesis by cartilage explant
5. Increased expression of pro MMP-3 by cultured chondrocytes
6. Increased expression of MMP-1 in cultured chondrocytes
7. Stimulation of collagenase-mediated type II collagen cleavage in cartilage explant
8. Stimulation of denaturation of type II collagen in cartilage explant
9. Increased expression of pro MMP-3 in cartilage explant
10. Increased expression of pro MMP-13 in cartilage explant
11. Increased expression of inducible nitric oxide synthetase mRNA in cultured chondrocytes
12. Increased nitric oxide production by cultured chondrocytes
13. Increased expression of interleukin 1 mRNA in cultured chondrocytes
14. Tyrosine phosphorylation of focal adhesion kinase (FAK) in cultured chondrocytes
15. Activation of extracellular signal-regulated kinase (ERK) in cultured chondrocytes
16. Activation of c-Jun NH2-terminal kinase (JNK) in cultured chondrocytes
17. Activation of p38 mitogen-activated protein kinase (MAPK) in cultured chondrocytes
18. Increased expression of CD44 mRNA and protein in cultured chondrocytes.How to heal FN-fragment-induced OA?
Consistent with a prominent role for integrins in FN
fragment-mediated chondrolysis, RGD peptides and their
analogs have been observed to mimic or block such effects
in vitro16,18,19. Additionally, an antisense oligonucleotide
specific for the 5 integrin subunit was recently found to
inhibit FN fragment-mediated suppression of proteoglycan
and protein synthesis in cartilage explants and chondro-
cytes43. However, no study has yet demonstrated inhibitionof such chondrolytic effects by an anti-integrin antibody,
potentially reflecting participation of multiple integrins in
these processes. As proposed in the model shown in Fig. 1,
catabolic responses are favored by reduced clustering of
integrins at the chondrocyte surface in response to
stretches of FN sequence. If valid, this model would predict
that functional blockade of one or more integrins could
further reduce the apparent complement of engaged recep-
tors, thereby augmenting rather than inhibiting catabolic
responses to FN fragments. Consistent with such a scen-
ario, a blocking antibody to the 51 receptor was recently
observed to promote proteoglycan degradation in bovine
cartilage explants43. Theoretically, a more effective exper-
imental approach to the inhibition of FN fragment-mediated
834 J. H. Peters et al.: Is osteoarthritis a ‘fibronectin-integrin imbalance disorder’?chondrolysis might be to use integrin-activating anti-
bodies44, thereby mimicking engagement of longer
stretches of FN at the chondrocyte surface.
If OA is indeed a ‘fibronectin-integrin imbalance dis-
order’, then how can it be prevented or cured? Based upon
in vitro studies, hyaluronic acid therapy appears to palliate
FN-mediated arthritis through induction of proteoglycan
synthesis40. This is certainly a good thing, but if FN
fragments actually contribute to the pathogenesis of OA,
we would like to go to the root of the problem. Logic would
suggest that the best way to prevent FN fragment-mediated
effects would be to go after the fragments before they can
cause problems, either by preventing their generation or by
neutralizing their effects. With respect to the former
approach, antiprotease therapy could prevent fragment
generation, but much work needs to be done to determine
which proteases should be inhibited45. With respect to the
latter approach, the most likely candidate receptors for FN
fragments on chondrocytes are integrins32–34, and these
would therefore appear to constitute targets for therapeutic
intervention in OA. However, several questions need to be
answered before specific molecular targets can be postu-
lated. For example, we need to determine the specific FN
fragments that trigger the most cartilage damage in clinical
OA, and how these partial FNs are recognized by chondro-
cytes, whether it is by integrins or other receptors. With this
knowledge, it should be possible to test appropriate mol-
ecular antagonists directed to specific globular domains or
FN. Given that the detrimental effects of FN fragments may
be dependent upon a selective reduction in integrin recog-
nition at the chondrocyte surface, it is also conceivable that
integrin agonists might be considered as therapeutic
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